RDP Pharma

Executive Summary

RDP Pharma AG is a privately-held Swiss biotech company founded in 2003 and headquartered in Geneva. The company specializes in innovative drug delivery and protein modulation technologies, with a particular focus on targeting historically 'undruggable' proteins that contain intrinsically disordered regions (IDRs). Its proprietary PromptDegrader™ platform aims to degrade these challenging proteins, offering a novel therapeutic approach for diseases with high unmet need. While RDP Pharma has remained under the radar with no disclosed funding rounds or pipeline details, its technology addresses a significant area of interest in targeted protein degradation, a field that has attracted substantial investment from major pharma. The company's long history suggests a disciplined, research-driven approach, though the lack of public milestones or partnerships makes it difficult to assess near-term commercial potential. Overall, RDP Pharma represents an early-stage platform play with promising technology but limited visibility into execution timelines or clinical progress.

Upcoming Catalysts (preview)

• Q3 2026Lead Program Candidate Selection50% success
• TBDSeries A or B Financing Round60% success
• TBDResearch Collaboration or Licensing Deal40% success